To assess safety, pharmacokinetics and the effect of dabigatran on coagulation parameters prior to administration of a high dose of dabigatran etexilate in a QT study
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
10
Frequency [N (%)] of subjects with adverse events
Time frame: up to 18 days
Cmax (maximum measured concentration of free and total BIBR 953 ZW in plasma)
Time frame: up to 72 hours after administration
tmax (time from dosing to maximum measured concentration)
Time frame: up to 72 hours after administration
AUC0-∞ (area under the concentration-time curve of free and total BIBR 953 ZW in plasma over the time interval from 0 extrapolated to infinity)
Time frame: up to 72 hours after administration
λz (terminal rate constant in plasma)
Time frame: up to 72 hours after administration
t1/2 (terminal half-life of the analyte in plasma)
Time frame: up to 72 hours after administration
MRTpo (mean residence time of the analyte in the body after oral administration)
Time frame: up to 72 hours after administration
CL/F (apparent clearance of the analyte in plasma after extravascular administration)
Time frame: up to 72 hours after administration
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Time frame: up to 72 hours after administration
Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: up to 72 hours after administration
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
Time frame: up to 72 hours after administration
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
Time frame: up to 72 hours after administration